Background: Treatment dropout in substance use disorder (SUD) programs poses a significant challenge to achieving successful outcomes and leads to legal and financial issues. Socioeconomic factors have been identified as key contributors to treatment attrition; yet, the specific impact of patients’ socioeconomic conditions remains underexplored. The purpose of this study is to examine the relationship between socioeconomic factors and SUD treatment dropout. Methods: We conducted a retrospective analysis of socioeconomic factors associated with treatment dropout among individuals with alcohol, marijuana, and heroin substance abuse. Logistic regression was used to examine the association between patients’ socioeconomic factors and treatment dropout. Adjusted odds ratios were calculated to quantify the strength of these associations. Results: Our findings demonstrate that demographic factors and financial status, including age (12–19 years), Black or African American race, and reliance on public assistance, correlate with an increased likelihood of treatment dropout. Black or African American patients receiving public assistance exhibit elevated dropout rates in ambulatory services, while patients of other single races without private insurance show higher dropout rates in detox services. Individuals aged 18–49 who are not part of the labor force have increased dropout rates in rehab services. Interestingly, patients in dependent living situations, who pay for services through private insurance or receive them at no charge, experience lower dropout rates as the number of arrests increases. Conversely, independently living patients with prior SUD treatments have higher dropout rates compared to those undergoing treatment for the first time. Conclusions: This study underscores the critical importance of addressing financial barriers to treatment access and retention in order to improve outcomes for individuals with substance use disorders (SUDs). Targeted interventions that support economically disadvantaged populations are essential for reducing treatment dropout rates and enhancing the effectiveness of SUD treatment programs.
We previously reported that human cytomegalovirus (HCMV) utilizes the cellular protein WDR5 to facilitate capsid nuclear egress. Here, we further show that HCMV infection drives WDR5 to the perinuclear region by a mechanism that requires viral replication and intact microtubules. WDR5 accumulated in the virion assembly compartment (vAC) and co-localized with vAC markers of gamma-tubulin (γ-tubulin), early endosomes, and viral vAC marker proteins pp65, pp28, and glycoprotein B (gB). WDR5 interacted with multiple virion proteins, including MCP, pp150, pp65, pIRS1, and pTRS1, which may explain the increasing WDR5 accumulation in the vAC during infection. WDR5 was then incorporated into HCMV virions and localized to the tegument layer, as demonstrated by fractionation and immune-gold electron microscopy. Thus, WDR5 is driven to the vAC and incorporated into virions, suggesting that WDR5 facilitates HCMV replication at later stage of virion assembly besides the capsid nuclear egress stage. These data highlight that WDR5 is a potential target for antiviral therapy. Importance: Human cytomegalovirus (HCMV) has a large (~235-kb) genome that contains over 170 ORFs and exploits numerous cellular factors to facilitate its replication. In the late phase of HCMV infection cytoplasmic membranes are profoundly reconfigured to establish the virion assembly compartment (vAC), which is important for efficient assembly of progeny virions. We previously reported that WDR5 promotes HCMV nuclear egress. Here, we show that WDR5 is further driven to the vAC and incorporated into virions, perhaps to facilitate efficient virion maturation. This work identified potential roles for WDR5 in HCMV replication in the cytoplasmic stages of virion assembly. Taken together, WDR5 plays a critical role in HCMV capsid nuclear egress and is important for virion assembly, and thus is a potential target for antiviral treatment of HCMV-associated diseases.